<p>Researcher from University of Griffith recently opens a mysterious cover over treatment of Parainfluenza Virus, According report there is no any drug or vaccine available to treat infection of Parainfluenza virus which causes an acute respiratory tract infection and WHO  reports suggests this is the second most prevalent cause of acute respiratory tract infection in infants in the world.</p><p>Researchers from University of Griffith suggests that an antiseptic drug generally used for treatment of sleeping sickness named “Suramin” and an anti-influenza virus drug “Relenza” when combine together then had high capacity to treat the infection of Parainfluenza virus.<br /><br />rnAccording to Researcher, Professor von Itzstein</p><p>&amp;quot;This study offers a potentially exciting avenue for the treatment of parainfluenza infection by using a combining and repurposing approach of well-established approved drugs,&amp;quot; he said.</p><p>&amp;quot;Together they complement each other to inhibit parainfluenza growth and may mean it can be prescribed as a lower dosage of each for treatment.</p><p>Please note that Professor von Itzstein is one of co-discoverer of World&amp;rsquo;s first anti flu drug named “Relenza”. The research is published in the Nature journal Scientific Reports, titled &#039;A dual drug regimen synergistically blocks human parainfluenza virus infection&#039;.</p><p>Note: The above story is for information purposes, for more information go through original story source.</p><p><strong>Story source:</strong> University of Griffith</p><p>Journal References:</p><p>Benjamin Bailly, Larissa Dirr, Ibrahim M. El-Deeb, Ralf Altmeyer, Patrice Guillon, Mark von Itzstein. A dual drug regimen synergistically blocks human parainfluenza virus infection. Scientific Reports, 2016; 6: 24138 DOI: 10.1038/srep2413</p>